Comparison of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in patients with thyroiditis and papillary tumors

Aziz Ari¹ and Feray Gunver²

Abstract

Objective: The neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) have recently been introduced as prognostic markers of thyroid cancer and strong inflammatory markers. The study was performed to investigate the association of the PLR and NLR with thyroid inflammation and papillary cancer.

Methods: Patients with thyroiditis and patients with papillary carcinomas were compared with sex-, age-, and body mass index-matched healthy controls. The NLR and PLR were calculated and compared among the three groups.

Results: The NLR was significantly higher in patients with thyroiditis and non-significantly higher in patients with papillary cancer than in healthy controls. The PLR was significantly higher in both patients with thyroiditis and papillary cancer than in healthy controls. Like the NLR, the PLR was not different between patients with thyroiditis and papillary cancer. The NLR was significantly and positively associated with the PLR and white blood cell count.

Conclusion: The PLR and NLR showed similar results in both thyroid inflammation and cancer. It seems difficult to obtain clear results in separating cancer from inflammatory events using these parameters. We suggest using them as supportive parameters of thyroid papillary cancer or inflammation.

¹Department of General Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey
²Department of Pathology, Istanbul Training and Research Hospital, Istanbul, Turkey

Corresponding author:
Aziz Ari, Department of General Surgery, Istanbul Training and Research Hospital, Kasap Ilyas Mah, Org. Abdurrahman Nafiz Gürün Cd., 34098 Fatih/Istanbul, Turkey.
Email: azizari02@hotmail.com
Introduction

Recent studies have revealed novel evidence that inflammation is related to cancer pathophysiology.\textsuperscript{1} The neutrophil–lymphocyte ratio (NLR) has recently been shown to serve as an independent prognostic factor in patients with cancer.\textsuperscript{2,3} This parameter is readily available from routine analyses and is therefore a convenient prognostic marker in such patients. In contrast to the NLR, the platelet–lymphocyte ratio (PLR) has been accepted as a novel biomarker. Platelets are inflammatory markers and are used to monitor the progression of tumoral invasion.\textsuperscript{4} Both of these markers are practical and reproducible at almost no extra cost and have been shown to improve the ability to assess the prognosis in patients with cancer.\textsuperscript{5}

Papillary thyroid malignancy is the most common type of thyroid carcinoma.\textsuperscript{6} Although the prognosis is generally good, the local and regional recurrence rates remain high.\textsuperscript{7} Unlike other types of cancers, few studies of thyroid cancer and its association with inflammation have been published.\textsuperscript{8} In a recent study, Seretis et al.\textsuperscript{9} evaluated the NLR in patients with papillary carcinoma and reported higher NLR levels in carcinoma. Another study showed a correlation between the preoperative NLR and tumor characteristics, with a significantly higher NLR in larger thyroid tumors.\textsuperscript{10} However, no further study has been performed to investigate the association between the PLR and papillary thyroid cancer in addition to the NLR. Although the NLR and PLR are currently accepted as prognostic markers for thyroid cancer, both of these parameters also increase in patients with inflammatory conditions of the thyroid. Although no association between papillary cancers and thyroiditis has been proven, inflammation is the common point of these diseases.

The present study was performed to investigate the NLR and PLR in patients with papillary thyroid cancer and thyroiditis to clarify whether alterations in the NLR and PLR are mainly affected by papillary cancer or thyroiditis.

Methods

The study involved patients with thyroiditis, patients with papillary carcinoma, and age-, sex-, and body mass index-matched healthy control subjects who visited the General Surgery Clinic at Istanbul Training and Research Hospital from 2014 to 2017. Approval for the study was granted by the Ethics Committee of Istanbul Research Hospital. All study participants provided written informed consent. All patients with thyroiditis and carcinoma were histopathologically diagnosed, and detailed demographic data were recorded.

Laboratory assessment

Biochemical analyses and blood counts were measured on the day of surgery. The NLR and PLR were calculated from the neutrophil, platelet, and lymphocyte ratios after performing a full blood count, which was analyzed with the impedance method using an XT-2000i hematology analyzer.
biochemical parameters were measured with standard methods on a clinical chemistry autoanalyzer (Cobas c501-e601; Roche, Basel, Switzerland) using the original test kits.

**Statistical analysis**

All patient data are presented as mean ± standard deviation. Multi-group analysis of variance was used to find significant differences among the mean values. Tukey’s B test was used for post-hoc analysis on subgroup comparisons. The one-tailed Pearson’s correlation test was applied to investigate correlations between variables. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22 (IBM Corp., Armonk, NY, USA).

**Results**

This study included 50 patients with thyroiditis, 50 patients with papillary carcinoma, and 46 age-, sex-, and body mass index-matched healthy control subjects. All participants’ PLR, NLR, biochemical and hematological parameters, and demographic characteristics are shown in Table 1. There were no significant differences in demographic data among the groups. Each group was compared with the others using post-hoc analysis. The mean NLR was significantly higher in the thyroiditis group (2.42±1.40, p=0.017) and non-significantly higher in the papillary cancer group (2.14±0.90) than in the healthy group (1.89±0.70). No significant difference was observed between the thyroiditis and papillary cancer groups (Figure 1).

The mean PLR was significantly higher in both the thyroiditis group (139.1±52.0, p<0.001) and papillary cancer group (136.7±57.0, p=0.003) than in the healthy group (107.0±22.3). No significant difference was observed between the thyroiditis and thyroid papillary cancer groups (Figure 2).

The fasting glucose, creatinine, aspartate transaminase, alanine transaminase, and

| Table 1. NLR, PLR, laboratory parameters, and demographic characteristics of each group |
|---------------------------------------------------------------|
| Parameters                | Healthy       | Thyroiditis    | Thyroid carcinoma |
|---------------------------|---------------|----------------|-------------------|
| Age (years)               | 45±10         | 48±10          | 46±12             |
| Sex (female/male)         | 32/14         | 38/12          | 36/14             |
| BMI (kg/m²)               | 26.8±5.3      | 25.1±6.2       | 28.3±4.7          |
| Nodule size (cm)          | 0.0±0.0       | 3.4±0.8        | 1.9±1.0           |
| Hemoglobin (g/dL)         | 12.8±1.1      | 13.0±1.2       | 12.8±1.2          |
| WBC (10³/µL)              | 7.02±1.27     | 7.30±1.93      | 7.62±2.10         |
| NEUT (10³/µL)             | 4.04±1.05     | 4.42±1.55      | 5.85±10.00        |
| PLAT (10³/µL)             | 260±64        | 264±71         | 272±67            |
| LYMP (10³/µL)             | 2.24±0.57     | 2.17±0.80      | 2.40±1.05         |
| NLR (Ratio)               | 1.89±0.70     | 2.40±1.40      | 2.14±0.90         |
| PLR (Ratio)               | 107.0±22.3    | 139.1±52.0     | 136.7±57.0        |
| FASTGLU (mg/dL)           | 95±12         | 108±36         | 97±22             |
| Creatinine (mg/dL)        | 0.92±0.10     | 0.87±0.18      | 0.82±0.21         |
| AST (IU/L)                | 22.0±9.1      | 22.0±11.4      | 20.0±10.5         |
| ALT (IU/L)                | 22.0±9.3      | 22.0±10.2      | 20.0±12.7         |
| TSH (mIU/L)               | 2.38±1.10     | 1.71±1.32      | 1.65±1.23         |

Abbreviations: BMI, body mass index; WBC, white blood cells; NEUT, neutrophils; PLAT, platelets; LYMP, lymphocytes; AST, aspartate transaminase; ALT, alanine transaminase; TSH, thyroid-stimulating hormone; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; FASTGLU, fasting glucose
thyroid-stimulating hormone (TSH) concentrations were similar in all groups. As shown in Table 2, a Pearson test was performed on each variable to investigate the correlation of the variable with the NLR. A strong positive correlation was found between the NLR and PLR ($r=0.682$, $p<0.001$), a weak positive correlation was found between the NLR and the white blood cell count ($r=0.285$, $p=0.025$), and no correlation was found between the NLR and the nodule diameter, age, or TSH level. In the thyroiditis group, significant correlations were found only between the NLR and PLR ($r=0.711$, $p<0.001$).

**Discussion**

In this study, we investigated the relationships of thyroiditis and papillary tumors with the NLR and PLR, which are known indicators of inflammation. Recent studies have shown that inflammation is associated with the cancer prognosis. Underlying
mechanisms and diagnostic biomarkers have been investigated in detail over the last decade. The results of these studies have suggested that the PLR and NLR are strong potential parameters for both cancer and inflammation of the thyroid because the assays are simple, inexpensive, and reproducible.\textsuperscript{11–13} In the current study, the NLR and PLR were compared between healthy control subjects and patients with thyroiditis and papillary cancer to clarify this point, and the results showed that the NLR was significantly higher in patients with thyroiditis than in healthy controls while the PLR was higher in both patients with papillary cancer and thyroid inflammation than in healthy controls. However, these increases did not show evidence of being specific to inflammation or papillary cancer.

Increasing evidence supports the involvement of systemic inflammation in cancer development and progression.\textsuperscript{14} In various types of cancer, the degree of systemic inflammation reflects the tumor burden.\textsuperscript{15} Evidence of systemic inflammation, as marked by leukocytosis or an elevated C-reactive protein level, is a known poor prognostic factor in cancers; additionally, such markers portend a worse prognosis and response to therapy.\textsuperscript{16} The NLR reflects the balance between innate (neutrophils) and adaptive (lymphocytes) immune responses.\textsuperscript{17} A high NLR reflects an augmented inflammatory reaction, which in turn correlates with decreased tumor-specific immunity.\textsuperscript{18} Moreover, the NLR has been shown to be a convenient and inexpensive prognostic biomarker in human cancers.

The NLR has been investigated in patients with malignancies of the pancreas, colon, liver, and lung. Although conflicting results have been obtained,\textsuperscript{19} a strong meta-analysis performed by Templeton et al.\textsuperscript{20} showed that the NLR was associated with survival in several solid tumors. Measurement of the preoperative NLR might also indicate activation of the systemic inflammatory response. In a study by Gong et al.,\textsuperscript{21} a positive association was demonstrated between a high NLR and advanced-stage disease in patients with papillary tumors. That report supports the importance of the NLR in evaluating thyroid carcinoma. In another related study, Seretis et al.\textsuperscript{9} investigated the NLR in patients with incidental papillary tumors and those with benign goiter. Higher NLRs were reported in patients with carcinoma than in those with goiter. Similarly, in the current study, the NLR was significantly higher in the patients with papillary carcinoma than in the healthy individuals, but it was not higher than that in patients with thyroiditis.

Table 2. Pearson correlation between NLR and other parameters in papillary cancer

| Variables | Coefficient | p-value |
|-----------|-------------|---------|
| Age       | 0.072       | 0.385   |
| Nodule size | 0.102       | 0.313   |
| TSH       | −0.015      | 0.856   |
| WBC       | 0.286\*     | 0.025   |
| PLR       | 0.682\**    | 0.001   |

Abbreviations: NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; WBC, white blood cells; TSH, thyroid-stimulating hormone.

\*p\textless{}0.05, \**p\textless{}0.001

The PLR is a valuable inflammatory index.\textsuperscript{22} It has also been suggested as a prognostic marker in several types of cancers, including gastric, ovarian, colorectal, and pancreatic cancer and cholangiocarcinoma.\textsuperscript{23} In breast cancer, an elevated PLR has been found to adversely impact survival in a few studies.\textsuperscript{3} The PLR is being accepted as another novel inflammatory marker that has been reported to be biochemically involved in the progression of tumor invasion. Recent studies have shown the potential for use of the PLR in a diagnostic approach to inflammatory events and malignancy.\textsuperscript{24} In the current study, the
PLR and NLR were higher in patients with papillary carcinoma than in healthy individuals. However, only the increased PLR was of statistical significance. In support of these results, Liu et al.\textsuperscript{25} performed a systematic meta-analysis based on 7 prospective cohort studies comprising 7349 patients and reported that an elevated NLR was not a reliable indicator of differentiated thyroid cancers in patients with goiters. In addition, Manatakis et al.\textsuperscript{26} reported that the NLR was not associated with sex, age, tumor size, tumor subtype, the presence of thyroiditis, or the TNM stage. Similarly, in the current study, no correlation was found between the NLR and age, nodule size, or TSH level, demonstrating that the PLR not only had a strong correlation with the NLR but was also significantly different from the NLR.

The findings of this study support previous findings in the literature showing that the NLR and PLR have potential in both malignancy and inflammatory events of thyroid tissue. However, this potential was stronger for the PLR than NLR. The present findings indicated a greater increase in the PLR than NLR in thyroid tissue. Even more importantly, both of these parameters showed similar results in thyroid inflammation and cancer. Therefore, it would appear to be difficult to obtain clear results from the measurement of these markers in the differentiation of cancer from inflammatory events; therefore, they might be useful as supportive or warning markers, not diagnostic markers, for thyroid papillary cancer or inflammation.

**Declaration of conflicting interest**
The authors declare that there is no conflict of interest.

**Funding**
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**References**
1. Karki R, Man SM and Kanneganti TD. Inflammasomes and cancer. *Cancer Immunol Res* 2017; 5: 94–99.
2. Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. *Crit Rev Oncol Hematol* 2013; 88: 218–230.
3. Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. *Br J Cancer* 2015; 113: 150–158.
4. Zheng J, Cai J, Li H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. *Cell Physiol Biochem* 2017; 44: 967–981.
5. Zhou Y, Wei Q, Fan J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. *Clin Chim Acta* 2018; 479: 181–189.
6. Nikiforov YE. Role of molecular markers in thyroid nodule management: then and now. *Endocr Pract* 2017; 23: 979–988.
7. Tafani M, De Santis E, Coppola L, et al. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. *Biomed Pharmacother* 2014; 68: 1–5.
8. Ehlers M and Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab 2014; 25: 656–664.

9. Seretis C, Gourgiotis S, Gemenetzis G, et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013; 205: 691–696.

10. Olsson AK and Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets 2018; 29: 569–573.

11. Dupré A and Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol 2018; 44: 566–570.

12. Mazza MG, Lucchi S, Tringali AGM, et al. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 84: 229–236.

13. Zhao Z, Zhao X, Lu J, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet 2018; 297: 849–857.

14. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436–444.

15. Can C, Baseskioglu B, Yilmaz M, et al. Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma. Urol Int 2012; 89: 468–472.

16. Kanat BH, Özkan Z, Bozan MB, et al. The Comparison Of Elective Repair Versus Emergency Surgery In The Elderly Patients With Ventral Hernia. Deu Med J 2018; 32(1): 15–21.

17. Marchioni M, Primiceri G, Ingrosso M, et al. The clinical use of the Neutrophil to Lymphocyte Ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer 2016; 14: 473–484.

18. Formica V, Lucechetti J, Cunningham D, et al. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol 2014; 31: 166.

19. Yersal O, Çetinkünar S, Aktimur R, et al. Neutrophil/lymphocyte and platelet/lymphocyte ratios are not different among breast cancer subtypes. Asian Pac J Cancer Prev 2017; 18: 2227–2231.

20. Templeton AJ, McNamara MG, Şeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.

21. Gong W, Yang S, Yang X, et al. Blood pre-operative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo) 2016; 71: 311–314.

22. Ulutas KT, Sarici IS and Arpaci A. Comparison of platelet distribution width and CA19-9 in resectable pancreas cancer. Med Arch 2018; 72: 210–213.

23. Zou ZY, Liu HL, Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett 2016; 11: 2241–2248.

24. Mehmet BC and Songul C. Correlation Between Clot Load Burden with Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Patients with Acute Pulmonary Embolism. Ulutas Med J 2017; 3(1): 13–19.

25. Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis. Sci Rep 2016; 6: 38551.

26. Manatakis DK, Tseleni-Balafouta S, Balalis D, et al. Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma. Int J Endocrinol 2017; 2017: 8471235.